In the pre-specified in-study analysis based on pooled 9 mg and 12 mg retatrutide groups, 44 participants receiving retatrutide experienced a MACE-5 event, defined as all-cause death, myocardial infarction, stroke, heart failure event, or coronary revascularization, compared with 52 participants receiving placebo, corresponding to a hazard ratio of 0.82 (95% CI: 0.55-1.22)
There are also preliminary studies of the effects of the drug in preventing cancer, and for the treatment of Parkinsons and Alzheimers, although further studies are still needed to confirm their results
What intrigued me instantly was the texture
Pharmacy pathway: Ask Novi which compounding pharmacy fulfills prescriptions for your state and whether that pharmacy documents individualized medical need for each patient - the standard now expected under the post-shortage regulatory framework
This article provides an in-depth overview of Ozempic for prediabetes, including FDA approval limitations, insurance considerations, cost, alternatives, and patient assistance options
Pharmacists can ask: how are you finding movement